CA2796978C - A process for particle processing of active pharmaceutical ingredients - Google Patents
A process for particle processing of active pharmaceutical ingredients Download PDFInfo
- Publication number
- CA2796978C CA2796978C CA2796978A CA2796978A CA2796978C CA 2796978 C CA2796978 C CA 2796978C CA 2796978 A CA2796978 A CA 2796978A CA 2796978 A CA2796978 A CA 2796978A CA 2796978 C CA2796978 C CA 2796978C
- Authority
- CA
- Canada
- Prior art keywords
- active pharmaceutical
- process according
- pharmaceutical ingredient
- solvent
- particle size
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000000034 method Methods 0.000 title claims abstract description 70
- 230000008569 process Effects 0.000 title claims abstract description 61
- 239000008186 active pharmaceutical agent Substances 0.000 title claims abstract description 49
- 239000002245 particle Substances 0.000 title claims abstract description 40
- 239000000843 powder Substances 0.000 claims abstract description 19
- 238000001694 spray drying Methods 0.000 claims abstract description 16
- 238000002955 isolation Methods 0.000 claims abstract description 9
- 238000001914 filtration Methods 0.000 claims abstract description 3
- 239000002904 solvent Substances 0.000 claims description 18
- 238000009826 distribution Methods 0.000 claims description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 14
- 230000009466 transformation Effects 0.000 claims description 10
- 239000000203 mixture Substances 0.000 claims description 9
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 claims description 8
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 8
- 210000004072 lung Anatomy 0.000 claims description 7
- 150000002148 esters Chemical class 0.000 claims description 6
- 229960004123 mometasone furoate monohydrate Drugs 0.000 claims description 6
- GIIZNNXWQWCKIB-UHFFFAOYSA-N Serevent Chemical compound C1=C(O)C(CO)=CC(C(O)CNCCCCCCOCCCCC=2C=CC=CC=2)=C1 GIIZNNXWQWCKIB-UHFFFAOYSA-N 0.000 claims description 5
- 229960000289 fluticasone propionate Drugs 0.000 claims description 5
- WMWTYOKRWGGJOA-CENSZEJFSA-N fluticasone propionate Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(OC(=O)CC)[C@@]2(C)C[C@@H]1O WMWTYOKRWGGJOA-CENSZEJFSA-N 0.000 claims description 5
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical group CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 4
- LERNTVKEWCAPOY-VOGVJGKGSA-N C[N+]1(C)[C@H]2C[C@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)C(O)(c1cccs1)c1cccs1 Chemical compound C[N+]1(C)[C@H]2C[C@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)C(O)(c1cccs1)c1cccs1 LERNTVKEWCAPOY-VOGVJGKGSA-N 0.000 claims description 4
- 229960001469 fluticasone furoate Drugs 0.000 claims description 4
- XTULMSXFIHGYFS-VLSRWLAYSA-N fluticasone furoate Chemical compound O([C@]1([C@@]2(C)C[C@H](O)[C@]3(F)[C@@]4(C)C=CC(=O)C=C4[C@@H](F)C[C@H]3[C@@H]2C[C@H]1C)C(=O)SCF)C(=O)C1=CC=CO1 XTULMSXFIHGYFS-VLSRWLAYSA-N 0.000 claims description 4
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- 229960000257 tiotropium bromide Drugs 0.000 claims description 4
- 229960001664 mometasone Drugs 0.000 claims description 3
- QLIIKPVHVRXHRI-CXSFZGCWSA-N mometasone Chemical group C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CCl)(O)[C@@]1(C)C[C@@H]2O QLIIKPVHVRXHRI-CXSFZGCWSA-N 0.000 claims description 3
- 229960005018 salmeterol xinafoate Drugs 0.000 claims description 3
- 230000000699 topical effect Effects 0.000 claims description 3
- XWTYSIMOBUGWOL-UHFFFAOYSA-N (+-)-Terbutaline Chemical compound CC(C)(C)NCC(O)C1=CC(O)=CC(O)=C1 XWTYSIMOBUGWOL-UHFFFAOYSA-N 0.000 claims description 2
- VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 claims description 2
- LUKZNWIVRBCLON-GXOBDPJESA-N Ciclesonide Chemical compound C1([C@H]2O[C@@]3([C@H](O2)C[C@@H]2[C@@]3(C[C@H](O)[C@@H]3[C@@]4(C)C=CC(=O)C=C4CC[C@H]32)C)C(=O)COC(=O)C(C)C)CCCCC1 LUKZNWIVRBCLON-GXOBDPJESA-N 0.000 claims description 2
- NDAUXUAQIAJITI-UHFFFAOYSA-N albuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-UHFFFAOYSA-N 0.000 claims description 2
- 229940092705 beclomethasone Drugs 0.000 claims description 2
- NBMKJKDGKREAPL-DVTGEIKXSA-N beclomethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O NBMKJKDGKREAPL-DVTGEIKXSA-N 0.000 claims description 2
- 229960002537 betamethasone Drugs 0.000 claims description 2
- UREBDLICKHMUKA-DVTGEIKXSA-N betamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-DVTGEIKXSA-N 0.000 claims description 2
- 229960004436 budesonide Drugs 0.000 claims description 2
- 229960003728 ciclesonide Drugs 0.000 claims description 2
- 229960002714 fluticasone Drugs 0.000 claims description 2
- MGNNYOODZCAHBA-GQKYHHCASA-N fluticasone Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(O)[C@@]2(C)C[C@@H]1O MGNNYOODZCAHBA-GQKYHHCASA-N 0.000 claims description 2
- 229960002848 formoterol Drugs 0.000 claims description 2
- BPZSYCZIITTYBL-UHFFFAOYSA-N formoterol Chemical compound C1=CC(OC)=CC=C1CC(C)NCC(O)C1=CC=C(O)C(NC=O)=C1 BPZSYCZIITTYBL-UHFFFAOYSA-N 0.000 claims description 2
- 229960000890 hydrocortisone Drugs 0.000 claims description 2
- 229960001888 ipratropium Drugs 0.000 claims description 2
- OEXHQOGQTVQTAT-JRNQLAHRSA-N ipratropium Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)[N@@+]2(C)C(C)C)C(=O)C(CO)C1=CC=CC=C1 OEXHQOGQTVQTAT-JRNQLAHRSA-N 0.000 claims description 2
- 229960002744 mometasone furoate Drugs 0.000 claims description 2
- WOFMFGQZHJDGCX-ZULDAHANSA-N mometasone furoate Chemical compound O([C@]1([C@@]2(C)C[C@H](O)[C@]3(Cl)[C@@]4(C)C=CC(=O)C=C4CC[C@H]3[C@@H]2C[C@H]1C)C(=O)CCl)C(=O)C1=CC=CO1 WOFMFGQZHJDGCX-ZULDAHANSA-N 0.000 claims description 2
- 229960002052 salbutamol Drugs 0.000 claims description 2
- 229960004017 salmeterol Drugs 0.000 claims description 2
- 150000003839 salts Chemical class 0.000 claims description 2
- 229960000195 terbutaline Drugs 0.000 claims description 2
- 229940110309 tiotropium Drugs 0.000 claims description 2
- LERNTVKEWCAPOY-DZZGSBJMSA-N tiotropium Chemical compound O([C@H]1C[C@@H]2[N+]([C@H](C1)[C@@H]1[C@H]2O1)(C)C)C(=O)C(O)(C=1SC=CC=1)C1=CC=CS1 LERNTVKEWCAPOY-DZZGSBJMSA-N 0.000 claims description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 1
- 150000001335 aliphatic alkanes Chemical class 0.000 claims 1
- 150000002576 ketones Chemical class 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 abstract description 5
- 239000000725 suspension Substances 0.000 description 32
- 239000000047 product Substances 0.000 description 16
- 238000010951 particle size reduction Methods 0.000 description 15
- 239000007921 spray Substances 0.000 description 8
- 239000003814 drug Substances 0.000 description 6
- 238000001035 drying Methods 0.000 description 6
- 238000009472 formulation Methods 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 229940079593 drug Drugs 0.000 description 5
- 239000011521 glass Substances 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 238000003756 stirring Methods 0.000 description 5
- 238000010902 jet-milling Methods 0.000 description 4
- 238000000634 powder X-ray diffraction Methods 0.000 description 4
- 239000007858 starting material Substances 0.000 description 4
- 238000012377 drug delivery Methods 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000002105 nanoparticle Substances 0.000 description 3
- 238000001238 wet grinding Methods 0.000 description 3
- 239000000654 additive Substances 0.000 description 2
- 238000000498 ball milling Methods 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000012467 final product Substances 0.000 description 2
- 239000010419 fine particle Substances 0.000 description 2
- 238000005243 fluidization Methods 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 230000000087 stabilizing effect Effects 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- HMUNWXXNJPVALC-UHFFFAOYSA-N 1-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)C(CN1CC2=C(CC1)NN=N2)=O HMUNWXXNJPVALC-UHFFFAOYSA-N 0.000 description 1
- VZSRBBMJRBPUNF-UHFFFAOYSA-N 2-(2,3-dihydro-1H-inden-2-ylamino)-N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]pyrimidine-5-carboxamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C(=O)NCCC(N1CC2=C(CC1)NN=N2)=O VZSRBBMJRBPUNF-UHFFFAOYSA-N 0.000 description 1
- WZFUQSJFWNHZHM-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)CC(=O)N1CC2=C(CC1)NN=N2 WZFUQSJFWNHZHM-UHFFFAOYSA-N 0.000 description 1
- CONKBQPVFMXDOV-QHCPKHFHSA-N 6-[(5S)-5-[[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]methyl]-2-oxo-1,3-oxazolidin-3-yl]-3H-1,3-benzoxazol-2-one Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)C[C@H]1CN(C(O1)=O)C1=CC2=C(NC(O2)=O)C=C1 CONKBQPVFMXDOV-QHCPKHFHSA-N 0.000 description 1
- KUVIULQEHSCUHY-XYWKZLDCSA-N Beclometasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)COC(=O)CC)(OC(=O)CC)[C@@]1(C)C[C@@H]2O KUVIULQEHSCUHY-XYWKZLDCSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 238000004497 NIR spectroscopy Methods 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- 238000000889 atomisation Methods 0.000 description 1
- 229950000210 beclometasone dipropionate Drugs 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 229960004648 betamethasone acetate Drugs 0.000 description 1
- AKUJBENLRBOFTD-QZIXMDIESA-N betamethasone acetate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)COC(C)=O)(O)[C@@]1(C)C[C@@H]2O AKUJBENLRBOFTD-QZIXMDIESA-N 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 239000002178 crystalline material Substances 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- MFBMYAOAMQLLPK-FZNHGJLXSA-N hydrocortisone aceponate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(C)=O)(OC(=O)CC)[C@@]1(C)C[C@@H]2O MFBMYAOAMQLLPK-FZNHGJLXSA-N 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000003049 inorganic solvent Substances 0.000 description 1
- 230000003434 inspiratory effect Effects 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 150000004682 monohydrates Chemical class 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 239000013557 residual solvent Substances 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 238000013341 scale-up Methods 0.000 description 1
- 238000005549 size reduction Methods 0.000 description 1
- CBHOWTTXCQAOID-UHFFFAOYSA-L sodium ethane formaldehyde mercury(2+) molecular iodine 2-sulfidobenzoate Chemical compound [Na+].[Hg++].C[CH2-].II.C=O.[O-]C(=O)c1ccccc1[S-] CBHOWTTXCQAOID-UHFFFAOYSA-L 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000008646 thermal stress Effects 0.000 description 1
- MQLXPRBEAHBZTK-SEINRUQRSA-M tiotropium bromide hydrate Chemical compound O.[Br-].C[N+]1(C)[C@H]2C[C@@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)C(O)(c1cccs1)c1cccs1 MQLXPRBEAHBZTK-SEINRUQRSA-M 0.000 description 1
- 238000010977 unit operation Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
- A61J3/02—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of powders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Emergency Medicine (AREA)
- Pulmonology (AREA)
- Otolaryngology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Plant Substances (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PT105058 | 2010-04-21 | ||
| PT105058A PT105058B (pt) | 2010-04-21 | 2010-04-21 | Processo para processamento de partículas de ingredientes activos farmacêuticos |
| PCT/GB2011/000631 WO2011131947A2 (en) | 2010-04-21 | 2011-04-21 | A process for particle processing of active pharmaceutical ingredients |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2796978A1 CA2796978A1 (en) | 2011-10-27 |
| CA2796978C true CA2796978C (en) | 2019-07-02 |
Family
ID=44194836
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2796978A Active CA2796978C (en) | 2010-04-21 | 2011-04-21 | A process for particle processing of active pharmaceutical ingredients |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US9956144B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP2560620B1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP6347608B2 (cg-RX-API-DMAC7.html) |
| CN (1) | CN102970978B (cg-RX-API-DMAC7.html) |
| BR (1) | BR112012026941A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2796978C (cg-RX-API-DMAC7.html) |
| IL (1) | IL222596B (cg-RX-API-DMAC7.html) |
| MX (1) | MX338594B (cg-RX-API-DMAC7.html) |
| PL (1) | PL2560620T3 (cg-RX-API-DMAC7.html) |
| PT (1) | PT105058B (cg-RX-API-DMAC7.html) |
| RU (1) | RU2597790C2 (cg-RX-API-DMAC7.html) |
| SG (1) | SG185003A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2011131947A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (59)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8691145B2 (en) | 2009-11-16 | 2014-04-08 | Flodesign Sonics, Inc. | Ultrasound and acoustophoresis for water purification |
| US10993879B2 (en) | 2010-02-08 | 2021-05-04 | Shenzhen Evergreen Therapeutics Co., Ltd. | Pulmonary delivery of progestogen |
| US10987361B2 (en) | 2010-02-08 | 2021-04-27 | Shenzhen Evergreen Therapeutics Co., Ltd. | Treating auto-immune and auto-inflammatory diseases |
| CN102811730B (zh) | 2010-02-08 | 2014-07-09 | 杜涛 | 孕激素作为糖皮质激素增敏剂的使用 |
| US9421553B2 (en) | 2010-08-23 | 2016-08-23 | Flodesign Sonics, Inc. | High-volume fast separation of multi-phase components in fluid suspensions |
| US10322949B2 (en) | 2012-03-15 | 2019-06-18 | Flodesign Sonics, Inc. | Transducer and reflector configurations for an acoustophoretic device |
| US9796956B2 (en) | 2013-11-06 | 2017-10-24 | Flodesign Sonics, Inc. | Multi-stage acoustophoresis device |
| US9688958B2 (en) | 2012-03-15 | 2017-06-27 | Flodesign Sonics, Inc. | Acoustic bioreactor processes |
| US9752113B2 (en) | 2012-03-15 | 2017-09-05 | Flodesign Sonics, Inc. | Acoustic perfusion devices |
| US9458450B2 (en) | 2012-03-15 | 2016-10-04 | Flodesign Sonics, Inc. | Acoustophoretic separation technology using multi-dimensional standing waves |
| US9752114B2 (en) | 2012-03-15 | 2017-09-05 | Flodesign Sonics, Inc | Bioreactor using acoustic standing waves |
| US9567559B2 (en) | 2012-03-15 | 2017-02-14 | Flodesign Sonics, Inc. | Bioreactor using acoustic standing waves |
| US9783775B2 (en) | 2012-03-15 | 2017-10-10 | Flodesign Sonics, Inc. | Bioreactor using acoustic standing waves |
| US10689609B2 (en) | 2012-03-15 | 2020-06-23 | Flodesign Sonics, Inc. | Acoustic bioreactor processes |
| US9745548B2 (en) | 2012-03-15 | 2017-08-29 | Flodesign Sonics, Inc. | Acoustic perfusion devices |
| US10370635B2 (en) | 2012-03-15 | 2019-08-06 | Flodesign Sonics, Inc. | Acoustic separation of T cells |
| US9950282B2 (en) | 2012-03-15 | 2018-04-24 | Flodesign Sonics, Inc. | Electronic configuration and control for acoustic standing wave generation |
| US9272234B2 (en) | 2012-03-15 | 2016-03-01 | Flodesign Sonics, Inc. | Separation of multi-component fluid through ultrasonic acoustophoresis |
| US10704021B2 (en) | 2012-03-15 | 2020-07-07 | Flodesign Sonics, Inc. | Acoustic perfusion devices |
| US11179747B2 (en) | 2015-07-09 | 2021-11-23 | Flodesign Sonics, Inc. | Non-planar and non-symmetrical piezoelectric crystals and reflectors |
| US10967298B2 (en) | 2012-03-15 | 2021-04-06 | Flodesign Sonics, Inc. | Driver and control for variable impedence load |
| PT106237B (pt) * | 2012-03-30 | 2015-03-19 | Hovione Farmaci Ncia S A | Produção de partículas substancialmente monodispersas utilizando moagem e separação por membranas |
| US10737953B2 (en) | 2012-04-20 | 2020-08-11 | Flodesign Sonics, Inc. | Acoustophoretic method for use in bioreactors |
| US11324873B2 (en) | 2012-04-20 | 2022-05-10 | Flodesign Sonics, Inc. | Acoustic blood separation processes and devices |
| PT106738B (pt) * | 2013-01-09 | 2015-06-08 | Hovione Farmaciencia Sa | Método para o controlo do fenómeno de degradação difusional de ostwald (ostwald ripening) no processamento de partículas de um ingrediente farmacêutico |
| SG11201508804QA (en) * | 2013-04-25 | 2015-11-27 | Flodesign Sonics Inc | Excipient removal from pharmacological samples |
| US9745569B2 (en) | 2013-09-13 | 2017-08-29 | Flodesign Sonics, Inc. | System for generating high concentration factors for low cell density suspensions |
| CN106061482A (zh) | 2013-10-08 | 2016-10-26 | 拉姆医疗公司 | 用于治疗淋巴管平滑肌瘤病的雷帕霉素 |
| EP3092049A1 (en) | 2014-01-08 | 2016-11-16 | Flodesign Sonics Inc. | Acoustophoresis device with dual acoustophoretic chamber |
| PT107433B (pt) * | 2014-01-28 | 2018-12-04 | Hovione Farm S A | Processo de redução e controlo do tamanho de partícula |
| US10307371B2 (en) | 2014-02-11 | 2019-06-04 | AI Therapeutics, Inc. | Rapamycin for the treatment of lymphangioleiomyomatosis |
| RU2016136348A (ru) | 2014-02-11 | 2018-03-16 | Лэм Терапьютикс, Инк. | Рапамицин для лечения лимфангиолейомиоматоза |
| PT107567B (pt) * | 2014-03-31 | 2019-02-13 | Hovione Farm S A | Secador por atomização com atomizador múltiplo, método para o aumento de escala de pós para inalação secos por dispositivo de atomização múltiplo e uso de vários atomizadores num secador por atomização |
| CN106659686A (zh) | 2014-04-04 | 2017-05-10 | 拉姆医疗公司 | 用于治疗年龄相关病况的可吸入雷帕霉素制剂 |
| US9744483B2 (en) | 2014-07-02 | 2017-08-29 | Flodesign Sonics, Inc. | Large scale acoustic separation device |
| KR20170095807A (ko) * | 2014-10-07 | 2017-08-23 | 램 테라퓨틱스, 인코포레이티드 | 폐 고혈압의 치료를 위한 흡입가능 라파마이신 제제 |
| MA40910A (fr) | 2014-11-07 | 2017-09-12 | Civitas Therapeutics Inc | Poudres de rapamycine pour administration pulmonaire |
| WO2016130645A1 (en) | 2015-02-10 | 2016-08-18 | Lam Therapeutics, Inc. | Rapamycin for the treatment of lymphangioleiomyomatosis |
| US10106770B2 (en) | 2015-03-24 | 2018-10-23 | Flodesign Sonics, Inc. | Methods and apparatus for particle aggregation using acoustic standing waves |
| PT108368B (pt) | 2015-03-31 | 2018-11-05 | Hovione Farm S A | Produção contínua de partículas |
| WO2016176663A1 (en) | 2015-04-29 | 2016-11-03 | Flodesign Sonics, Inc. | Acoustophoretic device for angled wave particle deflection |
| US11377651B2 (en) | 2016-10-19 | 2022-07-05 | Flodesign Sonics, Inc. | Cell therapy processes utilizing acoustophoresis |
| US11021699B2 (en) | 2015-04-29 | 2021-06-01 | FioDesign Sonics, Inc. | Separation using angled acoustic waves |
| US11708572B2 (en) | 2015-04-29 | 2023-07-25 | Flodesign Sonics, Inc. | Acoustic cell separation techniques and processes |
| BR112017024713B1 (pt) | 2015-05-20 | 2022-09-27 | Flodesign Sonics, Inc | Método para a separação de um segundo fluido ou um particulado de um fluido principal |
| WO2016201385A2 (en) | 2015-06-11 | 2016-12-15 | Flodesign Sonics, Inc. | Acoustic methods for separation cells and pathogens |
| US11034701B2 (en) | 2015-06-16 | 2021-06-15 | Nanophagix LLC | Drug delivery and imaging chemical conjugate, formulations and methods of use thereof |
| US11474085B2 (en) | 2015-07-28 | 2022-10-18 | Flodesign Sonics, Inc. | Expanded bed affinity selection |
| US11459540B2 (en) | 2015-07-28 | 2022-10-04 | Flodesign Sonics, Inc. | Expanded bed affinity selection |
| PT109030B (pt) | 2015-12-15 | 2019-09-25 | Hovione Farmaciência, S.A. | Preparação de partículas inaláveis de zafirlucaste |
| US10710006B2 (en) | 2016-04-25 | 2020-07-14 | Flodesign Sonics, Inc. | Piezoelectric transducer for generation of an acoustic standing wave |
| US11214789B2 (en) | 2016-05-03 | 2022-01-04 | Flodesign Sonics, Inc. | Concentration and washing of particles with acoustics |
| CA3023090A1 (en) | 2016-05-03 | 2017-11-09 | Flodesign Sonics, Inc. | Therapeutic cell washing, concentration, and separation utilizing acoustophoresis |
| US11085035B2 (en) | 2016-05-03 | 2021-08-10 | Flodesign Sonics, Inc. | Therapeutic cell washing, concentration, and separation utilizing acoustophoresis |
| CN110494543A (zh) | 2016-10-19 | 2019-11-22 | 弗洛设计声能学公司 | 通过声学的亲和细胞提取 |
| JP2021507561A (ja) | 2017-12-14 | 2021-02-22 | フロデザイン ソニックス， インク．Ｆｌｏｄｅｓｉｇｎ Ｓｏｎｉｃｓ， Ｉｎｃ． | 音響トランスデューサドライバ及びコントローラ |
| WO2022256720A2 (en) | 2021-06-03 | 2022-12-08 | Arcadia Medicine, Inc. | Enantiomeric entactogen compositions and methods of their use |
| EP4551196A1 (en) | 2022-07-04 | 2025-05-14 | Hovione Scientia Limited | Dry powder inhaler pharmaceutical composition of coated crystalline dry powder for inhalation |
| WO2025064867A1 (en) * | 2023-09-21 | 2025-03-27 | Yuva Biosciences, Inc. | Delivery system for mitochondrial health enhancers |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0725789B2 (ja) | 1990-09-10 | 1995-03-22 | シェリング・コーポレーション | フランカルボン酸モメタゾン―水和物、その製造法および医薬組成物 |
| US6187765B1 (en) * | 1997-10-09 | 2001-02-13 | Schering Corporation | Mometasone furoate suspensions for nebulization |
| US6184765B1 (en) * | 1999-01-07 | 2001-02-06 | Nec Research Institute, Inc. | Switch useful at superconducting temperatures and comprising superconducting material |
| US6555139B2 (en) * | 1999-06-28 | 2003-04-29 | Wockhardt Europe Limited | Preparation of micron-size pharmaceutical particles by microfluidization |
| GB9925934D0 (en) | 1999-11-03 | 1999-12-29 | Glaxo Group Ltd | Novel apparatus and process |
| GB0125604D0 (en) * | 2001-10-25 | 2001-12-19 | Glaxo Group Ltd | Novel process |
| JP4684545B2 (ja) | 2002-09-26 | 2011-05-18 | 大日本住友製薬株式会社 | 溶出性の良好なイソキサゾール誘導体経口製剤 |
| JP4875979B2 (ja) | 2004-03-31 | 2012-02-15 | 富山化学工業株式会社 | 難溶性薬物の微粒子分散液およびその製造方法 |
| EP1595534A1 (en) * | 2004-05-13 | 2005-11-16 | Universiteit Utrecht Holding B.V. | Gel composition comprising charged polymers |
| BRPI0517204A (pt) * | 2004-12-17 | 2008-09-30 | Cipla Ltd | sulfato de levosalbutamol cristalino (forma i), sulfato de levosalbutamol cristalino (forma ii), sulfato de levosalbutamol cristalino (forma iii), processo para preparar a forma i do sulfato de levosalbutamol cristalino, processo para preparar a forma ii do sulfato de levosalbutamol cristalino, processo para preparar a forma iii do sulfato de levosalbutamol, composição farmacêutica, composto, combinação, pó seco para inalador, processo para preparar um pó seco para inalador, processo para preparar uma composição famacêutica, processo para fabricação de uma composição farmacêutica, método para tratamento de um mamìfero, e uso de uma combinação de salbutamol |
| WO2006073154A1 (ja) | 2005-01-07 | 2006-07-13 | Eisai R&D Management Co., Ltd. | 医薬組成物及びその製造方法 |
| US20060193818A1 (en) * | 2005-02-25 | 2006-08-31 | Southall Michael D | Compositions containing amines and use thereof |
| DE102005011786A1 (de) | 2005-03-11 | 2006-09-14 | Pharmasol Gmbh | Verfahren zur Herstellung ultrafeiner Submicron-Suspensionen |
| GB0523576D0 (en) | 2005-11-18 | 2005-12-28 | Theradeas Ltd | Drug composition and its use in therapy |
| US20070178051A1 (en) | 2006-01-27 | 2007-08-02 | Elan Pharma International, Ltd. | Sterilized nanoparticulate glucocorticosteroid formulations |
| JP4879349B2 (ja) | 2007-07-31 | 2012-02-22 | 大塚製薬株式会社 | アリピプラゾール懸濁液及び凍結乾燥製剤の製造方法 |
| EP2050437A1 (en) | 2007-10-15 | 2009-04-22 | Laboratoires SMB | Improved pharmaceutical dry powder compositions for inhalation. |
| EP2156823A1 (en) * | 2008-08-14 | 2010-02-24 | Pharmatex Italia Srl | Process for the preparation of sterile powdered pharmeceutical compounds in the form of micro and nanoparticles |
-
2010
- 2010-04-21 PT PT105058A patent/PT105058B/pt active IP Right Grant
-
2011
- 2011-04-21 SG SG2012078614A patent/SG185003A1/en unknown
- 2011-04-21 CA CA2796978A patent/CA2796978C/en active Active
- 2011-04-21 CN CN201180024407.2A patent/CN102970978B/zh active Active
- 2011-04-21 RU RU2012149459/15A patent/RU2597790C2/ru active
- 2011-04-21 JP JP2013505534A patent/JP6347608B2/ja active Active
- 2011-04-21 PL PL11718765T patent/PL2560620T3/pl unknown
- 2011-04-21 WO PCT/GB2011/000631 patent/WO2011131947A2/en not_active Ceased
- 2011-04-21 MX MX2012012215A patent/MX338594B/es active IP Right Grant
- 2011-04-21 BR BR112012026941A patent/BR112012026941A2/pt not_active Application Discontinuation
- 2011-04-21 US US13/642,397 patent/US9956144B2/en active Active
- 2011-04-21 EP EP11718765.8A patent/EP2560620B1/en active Active
-
2012
- 2012-10-21 IL IL222596A patent/IL222596B/en active IP Right Grant
-
2016
- 2016-09-09 JP JP2016176303A patent/JP6857467B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN102970978B (zh) | 2017-05-10 |
| BR112012026941A2 (pt) | 2016-07-12 |
| SG185003A1 (en) | 2012-11-29 |
| MX338594B (es) | 2016-04-25 |
| EP2560620B1 (en) | 2020-09-16 |
| CN102970978A (zh) | 2013-03-13 |
| WO2011131947A3 (en) | 2012-01-05 |
| JP6857467B2 (ja) | 2021-04-14 |
| JP6347608B2 (ja) | 2018-06-27 |
| JP2017019845A (ja) | 2017-01-26 |
| IL222596B (en) | 2019-03-31 |
| PL2560620T3 (pl) | 2021-04-06 |
| WO2011131947A2 (en) | 2011-10-27 |
| US20130203717A1 (en) | 2013-08-08 |
| PT105058A (pt) | 2011-10-21 |
| EP2560620A2 (en) | 2013-02-27 |
| MX2012012215A (es) | 2013-05-09 |
| RU2597790C2 (ru) | 2016-09-20 |
| JP2013525338A (ja) | 2013-06-20 |
| CA2796978A1 (en) | 2011-10-27 |
| US9956144B2 (en) | 2018-05-01 |
| IL222596A0 (en) | 2012-12-31 |
| PT105058B (pt) | 2013-04-17 |
| RU2012149459A (ru) | 2014-05-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2796978C (en) | A process for particle processing of active pharmaceutical ingredients | |
| JP6499187B2 (ja) | 支援された粒子径低減方法 | |
| US20020081266A1 (en) | Spray dried powders for pulmonary or nasal administration | |
| CA2510263C (en) | Preparation of sterile aqueous suspensions comprising micronised crystalline active ingredients for inhalation | |
| JP2013525338A5 (cg-RX-API-DMAC7.html) | ||
| AU2008334547B2 (en) | Organic compounds | |
| EP3346990B1 (en) | Jet milling method | |
| CN108463213B (zh) | 可吸入扎鲁司特颗粒的制备 | |
| CN105120841A (zh) | 抗毒蕈碱化合物的粒度减小 | |
| KR102275109B1 (ko) | 미립자 결정질 재료를 컨디셔닝하는 방법 및 시스템 | |
| ES2831019T3 (es) | Un procedimiento para el procesamiento de partículas de ingredientes farmacéuticos activos | |
| CN112469443B (zh) | 用于吸入用干粉制剂的新型载体颗粒 | |
| CN119499184A (zh) | 一种微粉化原料药状态调节方法 | |
| HK40037203B (zh) | 用於吸入用干粉制剂的新型载体颗粒 | |
| HK1216302B (zh) | 抗毒蕈硷化合物的粒度减小 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20160311 |